Simon Haefliger

876 total citations · 1 hit paper
33 papers, 604 citations indexed

About

Simon Haefliger is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Simon Haefliger has authored 33 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Simon Haefliger's work include Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Nanoparticle-Based Drug Delivery (5 papers). Simon Haefliger is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Nanoparticle-Based Drug Delivery (5 papers). Simon Haefliger collaborates with scholars based in Switzerland, United States and Germany. Simon Haefliger's co-authors include Thomas Pabst, Julian Schardt, Beatrice U. Mueller, Marianne Eyholzer, Rory Johnson, Michela Coan, Samir Ounzain, Nikolai A. Timchenko, Milton J. Finegold and Jingling Jin and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Simon Haefliger

32 papers receiving 591 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting and engineering long non-coding RNAs for cancer therapy

2024 98 citations Simon Haefliger, Rory Johnson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Haefliger Switzerland	12	342	204	135	73	65	33	604
Chiqi Chen China	17	479 1.4×	244 1.2×	193 1.4×	142 1.9×	65 1.0×	34	792
Jianqing Huang China	9	284 0.8×	139 0.7×	61 0.5×	125 1.7×	50 0.8×	27	525
Andrea Kühnl United Kingdom	11	306 0.9×	111 0.5×	112 0.8×	207 2.8×	43 0.7×	34	632
Usawadee Dier United States	7	216 0.6×	126 0.6×	61 0.5×	61 0.8×	96 1.5×	9	409
Li Weng United States	11	312 0.9×	77 0.4×	129 1.0×	120 1.6×	40 0.6×	21	514
Chongyun Xing China	13	381 1.1×	275 1.3×	132 1.0×	141 1.9×	39 0.6×	30	559
Durga Attili United States	11	199 0.6×	111 0.5×	79 0.6×	111 1.5×	28 0.4×	16	436
Ahmed H. Mekkawy Australia	12	235 0.7×	146 0.7×	34 0.3×	105 1.4×	25 0.4×	27	466
Amy L. Pyle United States	10	263 0.8×	102 0.5×	50 0.4×	82 1.1×	87 1.3×	13	442

Countries citing papers authored by Simon Haefliger

Since Specialization

Citations

This map shows the geographic impact of Simon Haefliger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Haefliger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Haefliger more than expected).

Fields of papers citing papers by Simon Haefliger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Haefliger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Haefliger. The network helps show where Simon Haefliger may publish in the future.

Co-authorship network of co-authors of Simon Haefliger

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Haefliger. A scholar is included among the top collaborators of Simon Haefliger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Haefliger. Simon Haefliger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klose, Martina, Simon Haefliger, Manuela Rabaglio, et al.. (2025). 35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16). ESMO Open. 10. 104193–104193. 1 indexed citations

Pradervand, Sylvain, Rita Achermann, Simon Haefliger, et al.. (2024). Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers. SHILAP Revista de lepidopterología. 6. 100075–100075. 1 indexed citations

Vancura, Adrienne, et al.. (2024). Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC). British Journal of Cancer. 131(8). 1350–1362. 18 indexed citations

Colombo, Ilaria, Simon Haefliger, Manuela Rabaglio, et al.. (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European Journal of Cancer. 201. 113588–113588. 10 indexed citations

Hess, Dagmar, Robin Michelet, Ilaria Colombo, et al.. (2024). Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemotherapy and Pharmacology. 94(3). 349–360. 5 indexed citations

Haefliger, Simon, et al.. (2023). Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 16(1). 871–877. 1 indexed citations

Lopez, Juanita, Simon Haefliger, Ruth Plummer, et al.. (2023). Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.. Journal of Clinical Oncology. 41(16_suppl). 2044–2044. 1 indexed citations

Joerger, Markus, Simon Haefliger, Roger von Moos, et al.. (2023). Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational New Drugs. 41(2). 267–275. 1 indexed citations

Addeo, Alfredo, Sacha I. Rothschild, Martina Schneider, et al.. (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer. 172. 154–159. 13 indexed citations

10.

Britschgi, Christian, Sylvain Pradervand, Rita Achermann, et al.. (2022). Structure-based prediction of BRAF mutation classes using machine-learning approaches. Scientific Reports. 12(1). 12528–12528. 7 indexed citations

11.

Hess, Dagmar, Ilaria Colombo, Simon Haefliger, et al.. (2022). TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).. Journal of Clinical Oncology. 40(16_suppl). 3027–3027. 1 indexed citations

12.

Vancura, Adrienne, et al.. (2021). Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs. NAR Cancer. 3(2). zcab013–zcab013. 20 indexed citations

13.

Gettinger, Scott, Harriet M. Kluger, Adam J. Schoenfeld, et al.. (2021). Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors. Cancer Research. 81(13_Supplement). CT235–CT235. 1 indexed citations

14.

Addeo, Alfredo, Markus Joerger, Sacha I. Rothschild, et al.. (2021). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.. Journal of Clinical Oncology. 39(15_suppl). e21119–e21119. 4 indexed citations

15.

Hess, Dagmar, Ilaria Colombo, Simon Haefliger, et al.. (2020). 575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16). Annals of Oncology. 31. S490–S490. 2 indexed citations

16.

Haefliger, Simon, et al.. (2020). Diagnostic performance of direct immunofluorescence microscopy studies by biopsy sites in autoimmune subepidermal blistering dermatoses: a prospective study. British Journal of Dermatology. 183(5). 970–972. 1 indexed citations

17.

Hayes, Sarah A., Simon Haefliger, Benjamin Harris, et al.. (2016). Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. Journal of Breath Research. 10(3). 34001–34001. 38 indexed citations

18.

Wang, Guo-Li, Xiurong Shi, Simon Haefliger, et al.. (2010). Elimination of C/EBPα through the ubiquitin-proteasome system promotes the development of liver cancer in mice. Journal of Clinical Investigation. 120(7). 2549–2562. 50 indexed citations

19.

Jin, Jingling, Guoli Wang, Polina Iakova, et al.. (2010). Epigenetic changes play critical role in age‐associated dysfunctions of the liver. Aging Cell. 9(5). 895–910. 29 indexed citations

20.

Eyholzer, Marianne, Sabine Schmid, Julian Schardt, et al.. (2009). Complexity of miR-223 regulation by CEBPA in human AML. Leukemia Research. 34(5). 672–676. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact